SCHEMBL2967351

SCHEMBL2967351

COc1ccccc1Cc1nc2cc(-c3nn(C4CCC(O)CC4)c4ncnc(N)c34)ccc2[nH]1

nearest known ligand 0.73

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ IGF1R P08069 17/20 0.73
▸ EGFR P00533 14/20 0.73
▸ ERBB2 P04626 11/20 0.73
▸ CYP2D6 P10635 1/20 0.67
▸ BTK Q06187 1/20 0.55
▸ PIK3CD O00329 2/20 0.52
▸ ABL1 P00519 2/20 0.52
▸ HCK P08631 2/20 0.52
▸ SRC P12931 2/20 0.52
▸ KDR P35968 2/20 0.52
▸ PIK3CA P42336 2/20 0.52
▸ PIK3CB P42338 2/20 0.52
▸ MTOR P42345 2/20 0.52
▸ PIK3CG P48736 2/20 0.52
▸ EPHB4 P54760 2/20 0.52
▸ PRKDC P78527 2/20 0.52
▸ PI4KB Q9UBF8 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2967347 1.00 IGF1R (0.73) IGF1REGFRERBB2CYP2D6BTK
SCHEMBL2966259 0.95 IGF1R (0.77) IGF1REGFRERBB2CYP2D6
SCHEMBL2965509 0.91 IGF1R (0.63) IGF1REGFRERBB2CYP2D6
SCHEMBL2965505 0.91 IGF1R (0.63) IGF1REGFRERBB2CYP2D6
SCHEMBL2965673 0.90 IGF1R (0.90) IGF1REGFRERBB2CYP2D6
SCHEMBL2966866 0.90 IGF1R (0.78) IGF1REGFRERBB2CYP2D6SRC
SCHEMBL2966868 0.90 IGF1R (0.78) IGF1REGFRERBB2CYP2D6SRC
SCHEMBL2965676 0.90 IGF1R (0.90) IGF1REGFRERBB2CYP2D6
SCHEMBL2969406 0.89 IGF1R (0.90) IGF1REGFRERBB2CYP2D6
SCHEMBL2969408 0.89 IGF1R (0.90) IGF1REGFRERBB2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1973917-B1 PROTEIN KINASE INHIBITORS ABBVIE INC (US) 2015-06-10 — — EP claimed
US-7772231-B2 Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors ABBOTT LABORATORIES (US) 2010-08-10 — — US claimed
EP-1973917-B1 PROTEIN KINASE INHIBITORS ABBVIE INC (US) 2015-06-10 — — EP disclosed
US-7772231-B2 Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors ABBOTT LABORATORIES (US) 2010-08-10 — — US disclosed
EP-1973917-A2 PROTEIN KINASE INHIBITORS Abbott Laboratories (US) 2008-10-01 — — EP disclosed
US-20070203143-A1 PROTEIN KINASE INHIBITORS ABBVIE INC. 2007-08-30 — — US disclosed
WO-2007079164-A2 PROTEIN KINASE INHIBITORS ABBOTT LABORATORIES (US) 2007-07-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070203143-A1 PROTEIN KINASE INHIBITORS PACSIN2, MAP3K20, PHKG1 IGF1R 1941/4885EGFR 591/4885ERBB2 270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback